Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.

Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.

Mar 23, 2021

PHILADELPHIA and NEW YORK, March 23, 2021 /PRNewswire/ —┬áRenovacor, Inc. (“Renovacor” or the “Company”), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiovascular and central nervous system (CNS) diseases resulting from BAG3 gene dysfunction, and Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (“CHAQ”), a special purpose acquisition company or SPAC, sponsored by affiliates of Chardan Capital Markets (“Chardan”), announced today they have entered into a definitive business combination agreement. Upon closing of the transaction, CHAQ will be renamed Renovacor, Inc. and its common stock is expected to be listed on NYSE under the ticker symbol “RCOR” (the “Combined Company”).